Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma

A. Reardon, David; A. Brandes, Alba; Omuro, Antonio; Mulholland, Paul; Lim, Michael; Wick, Antje; M. Baehring, Joachim; S. Ahluwalia, Manmeet; Roth, Patrick; Bähr, Oliver; Phuphanich, Surasak; Manuel Sepúlveda-Sánchez, Juan; de Souza, Paul; Sahebjam, Solmaz; Carleton, Michael; Tatsuoka, Kay; Taitt, Corina; Zwirtes, Ricardo; H. Sampson, John; Weller, Michael

doi:10.1001/jamaoncol.2020.1024

Public

Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma

Published in JAMA Oncology • May 21, 2020

Authors:

David A. Reardon

Alba A. Brandes

Antonio Omuro

Abstract

Importance: Clinical outcomes for glioblastoma remain poor. Treatment with immune checkpoint blockade has shown benefits in many cancer types. To our knowledge, data from a randomized phase 3 clinical trial evaluating a programmed death-1 (PD-1) inhibitor therapy for glioblastoma have not been repor...

Subject

Medicine

Nivolumab

Bevacizumab

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!